11/20
11:09 am
txg
Spatial Genomics and Transcriptomics Research Analysis Report 2024-2030: Emergence of High-Throughput Sequencing Platforms Fuels Market Growth [Yahoo! Finance]
Low
Report
Spatial Genomics and Transcriptomics Research Analysis Report 2024-2030: Emergence of High-Throughput Sequencing Platforms Fuels Market Growth [Yahoo! Finance]
11/14
04:49 am
txg
Sphere Fluidics Strengthens Global Commercial Teams and Establishes Direct Sales and Support Channel in North America [Yahoo! Finance]
Medium
Report
Sphere Fluidics Strengthens Global Commercial Teams and Establishes Direct Sales and Support Channel in North America [Yahoo! Finance]
11/7
04:05 pm
txg
10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference
Medium
Report
10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference
11/1
10:35 am
txg
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Barclays PLC from $21.00 to $19.00. They now have an "overweight" rating on the stock.
Low
Report
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Barclays PLC from $21.00 to $19.00. They now have an "overweight" rating on the stock.
11/1
09:56 am
txg
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts [Yahoo! Finance]
Low
Report
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts [Yahoo! Finance]
10/31
08:00 am
txg
TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative
Low
Report
TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative
10/30
03:35 pm
txg
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Citigroup Inc. from $35.00 to $23.00. They now have a "buy" rating on the stock.
Low
Report
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Citigroup Inc. from $35.00 to $23.00. They now have a "buy" rating on the stock.
10/30
01:03 pm
txg
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at JPMorgan Chase & Co. from $20.00 to $14.00. They now have a "neutral" rating on the stock.
Low
Report
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at JPMorgan Chase & Co. from $20.00 to $14.00. They now have a "neutral" rating on the stock.
10/30
01:03 pm
txg
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $16.00 to $14.00. They now have a "sell" rating on the stock.
Low
Report
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $16.00 to $14.00. They now have a "sell" rating on the stock.
10/30
11:28 am
txg
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at UBS Group AG from $25.00 to $20.00. They now have a "neutral" rating on the stock.
Low
Report
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at UBS Group AG from $25.00 to $20.00. They now have a "neutral" rating on the stock.
10/29
04:05 pm
txg
10x Genomics Reports Third Quarter 2024 Financial Results
Medium
Report
10x Genomics Reports Third Quarter 2024 Financial Results
10/28
03:52 pm
txg
Lower Instruments Sales to Hurt TXG Q3 Earnings, Prelim Sales Down [Yahoo! Finance]
Low
Report
Lower Instruments Sales to Hurt TXG Q3 Earnings, Prelim Sales Down [Yahoo! Finance]
10/23
01:12 pm
txg
10x Genomics (TXG) Upgraded to Strong Buy: Here's Why [Yahoo! Finance]
Low
Report
10x Genomics (TXG) Upgraded to Strong Buy: Here's Why [Yahoo! Finance]
10/22
09:24 am
txg
Genoa Ventures Elevates Landon Merrill to Partner, Strengthening Leadership in Science-Driven Investing [Yahoo! Finance]
Low
Report
Genoa Ventures Elevates Landon Merrill to Partner, Strengthening Leadership in Science-Driven Investing [Yahoo! Finance]
10/22
09:21 am
txg
PacBio Onso™ Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program [Yahoo! Finance]
Low
Report
PacBio Onso™ Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program [Yahoo! Finance]
10/18
11:37 am
txg
Proteintech Genomics Launches the MultiPro® Human Discovery Panel: A New Frontier in Single-Cell Multiomics [Yahoo! Finance]
Low
Report
Proteintech Genomics Launches the MultiPro® Human Discovery Panel: A New Frontier in Single-Cell Multiomics [Yahoo! Finance]
10/17
09:31 am
txg
European Unified Patent Court Rules in Favor of Bruker and NanoString, Invalidating Patent Asserted By 10x Genomics against NanoString's CosMx SMI Products [Yahoo! Finance]
Medium
Report
European Unified Patent Court Rules in Favor of Bruker and NanoString, Invalidating Patent Asserted By 10x Genomics against NanoString's CosMx SMI Products [Yahoo! Finance]
10/15
04:05 pm
txg
10x Genomics Delivers 'Single Cell for a Single Cent' with New Chromium Launches
Low
Report
10x Genomics Delivers 'Single Cell for a Single Cent' with New Chromium Launches
10/15
02:49 pm
txg
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Barclays PLC from $24.00 to $21.00. They now have an "overweight" rating on the stock.
Low
Report
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Barclays PLC from $24.00 to $21.00. They now have an "overweight" rating on the stock.
10/10
12:31 pm
txg
10x Genomics, Inc. (NASDAQ: TXG) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $30.00 price target on the stock.
Low
Report
10x Genomics, Inc. (NASDAQ: TXG) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $30.00 price target on the stock.
10/10
11:47 am
txg
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $32.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $32.00 to $20.00. They now have a "buy" rating on the stock.
10/10
07:45 am
txg
Gene Sequencing Tech Provider 10x Genomics' Q3 Sales Fall Short On Expectations, But CEO Sees Opportunity Ahead [Yahoo! Finance]
Low
Report
Gene Sequencing Tech Provider 10x Genomics' Q3 Sales Fall Short On Expectations, But CEO Sees Opportunity Ahead [Yahoo! Finance]
10/9
04:58 pm
txg
Illumina introduces new DNA sequencing instruments, but Street unimpressed [Seeking Alpha]
Medium
Report
Illumina introduces new DNA sequencing instruments, but Street unimpressed [Seeking Alpha]
10/9
04:19 pm
txg
10x Genomics reports prelim revenue of $151.7M for Q3 [Seeking Alpha]
Low
Report
10x Genomics reports prelim revenue of $151.7M for Q3 [Seeking Alpha]
10/9
04:05 pm
txg
10x Genomics Announces Preliminary Select Third Quarter 2024 Results
High
Report
10x Genomics Announces Preliminary Select Third Quarter 2024 Results